12/09/2024 | Press release | Distributed by Public on 12/09/2024 20:21
Initial Results from the QTc Substudy of the IMerge Phase 3 Trial Demonstrate Clinically Meaningful Efficacy, Manageable Safety, and Absence of Proarrhythmic Risk in Patients[...]
